A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Exclusion Criteria

• •Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
• •Any evidence of tumor metastasis or co-existing malignant disease
• •Participants previously receiving any prior therapy for HCC, including loco-regional therapies
• •Participants who have undergone a liver transplant or those who are in the waiting list for liver transplantation
• •Participants who have received a live/attenuated vaccine within 30 days of randomization (eg, varicella, zoster, yellow fever, rotavirus, oral polio and measles, mumps, rubella \[MMR\]).